These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 26427033

  • 1. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM, Mumina A, Tayler-Smith K, Boulle P, Alcoba G, Elhag MS, Alnour M, Shah S, Chappuis F, van Griensven J, Zachariah R.
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [Abstract] [Full Text] [Related]

  • 2. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.
    Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN.
    Am J Trop Med Hyg; 2007 Jul; 77(1):89-94. PubMed ID: 17620635
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of a combined treatment of sodium stibogluconate at 20mg/kg/day with upper maximum daily dose limit of 850mg and Paromomycin 15mg/kg/day in HIV negative visceral leishmaniasis patients. A retrospective study, northwest Ethiopia.
    Tamiru A, Mohammed R, Atnafu S, Medhin G, Hailu A.
    PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009713. PubMed ID: 34464401
    [Abstract] [Full Text] [Related]

  • 4. Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
    Kimutai R, Musa AM, Njoroge S, Omollo R, Alves F, Hailu A, Khalil EA, Diro E, Soipei P, Musa B, Salman K, Ritmeijer K, Chappuis F, Rashid J, Mohammed R, Jameneh A, Makonnen E, Olobo J, Okello L, Sagaki P, Strub N, Ellis S, Alvar J, Balasegaram M, Alirol E, Wasunna M.
    Clin Drug Investig; 2017 Mar; 37(3):259-272. PubMed ID: 28066878
    [Abstract] [Full Text] [Related]

  • 5. Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial.
    Musa A, Khalil E, Hailu A, Olobo J, Balasegaram M, Omollo R, Edwards T, Rashid J, Mbui J, Musa B, Abuzaid AA, Ahmed O, Fadlalla A, El-Hassan A, Mueller M, Mucee G, Njoroge S, Manduku V, Mutuma G, Apadet L, Lodenyo H, Mutea D, Kirigi G, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tafes H, Mekonnen Y, Makonnen E, Ndegwa S, Sagaki P, Kimutai R, Kesusu J, Owiti R, Ellis S, Wasunna M.
    PLoS Negl Trop Dis; 2012 Mar; 6(6):e1674. PubMed ID: 22724029
    [Abstract] [Full Text] [Related]

  • 6. Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?
    Salih NA, van Griensven J, Chappuis F, Antierens A, Mumina A, Hammam O, Boulle P, Alirol E, Alnour M, Elhag MS, Manzi M, Kizito W, Zachariah R.
    Trop Med Int Health; 2014 Feb; 19(2):146-52. PubMed ID: 24433217
    [Abstract] [Full Text] [Related]

  • 7. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment.
    Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, Aboud MH, Noazin S, Ghalib HW, El-Hassan AM, Leishmaniasis Research Group/Sudan.
    Trans R Soc Trop Med Hyg; 2008 Jan; 102(1):58-63. PubMed ID: 17963805
    [Abstract] [Full Text] [Related]

  • 8. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan.
    Veeken H, Ritmeijer K, Seaman J, Davidson R.
    Trop Med Int Health; 2000 May; 5(5):312-7. PubMed ID: 10886792
    [Abstract] [Full Text] [Related]

  • 9. Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
    Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, Muthoni Ouattara G, Egondi T, Nakanwagi P, Omollo T, Wasunna M, Verrest L, Dorlo TPC, Musa Younis B, Nour A, Taha Ahmed Elmukashfi E, Ismail Omer Haroun A, Khalil EAG, Njenga S, Fikre H, Mekonnen T, Mersha D, Sisay K, Sagaki P, Alvar J, Solomos A, Alves F.
    Clin Infect Dis; 2023 Feb 08; 76(3):e1177-e1185. PubMed ID: 36164254
    [Abstract] [Full Text] [Related]

  • 10. Relationship between treatment regimens for visceral leishmaniasis and development of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse: A cohort study from Bangladesh.
    Mondal D, Kumar A, Sharma A, Ahmed MM, Hasnain MG, Alim A, Huda MM, Rahman R, Alvar J, Ahmed BN, Haque R.
    PLoS Negl Trop Dis; 2019 Aug 08; 13(8):e0007653. PubMed ID: 31415565
    [Abstract] [Full Text] [Related]

  • 11. A Comparison of the Effectiveness of Sodium Stibogluconate Monotherapy to Sodium Stibogluconate and Paromomycin Combination for the Treatment of Severe Post Kala Azar Dermal Leishmaniasis in South Sudan - A Retrospective Cohort Study.
    Abongomera C, Gatluak F, Buyze J, Ritmeijer K.
    PLoS One; 2016 Aug 08; 11(9):e0163047. PubMed ID: 27658288
    [Abstract] [Full Text] [Related]

  • 12. A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan.
    Mueller M, Balasegaram M, Koummuki Y, Ritmeijer K, Santana MR, Davidson R.
    J Antimicrob Chemother; 2006 Oct 08; 58(4):811-5. PubMed ID: 16916865
    [Abstract] [Full Text] [Related]

  • 13. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya.
    Moore E, O'Flaherty D, Heuvelmans H, Seaman J, Veeken H, de Wit S, Davidson RN.
    Bull World Health Organ; 2001 Oct 08; 79(5):388-93. PubMed ID: 11417033
    [Abstract] [Full Text] [Related]

  • 14. Expression profiling of Sudanese visceral leishmaniasis patients pre- and post-treatment with sodium stibogluconate.
    Salih MAM, Fakiola M, Lyons PA, Younis BM, Musa AM, Elhassan AM, Anderson D, Syn G, Ibrahim ME, Blackwell JM, Mohamed HS.
    Parasite Immunol; 2017 Jun 08; 39(6):. PubMed ID: 28370072
    [Abstract] [Full Text] [Related]

  • 15. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
    Gebreyohannes EA, Bhagvathula AS, Abegaz TM, Seid MA.
    Infect Dis Poverty; 2018 Oct 19; 7(1):108. PubMed ID: 30340519
    [Abstract] [Full Text] [Related]

  • 16. Visceral leishmaniasis relapse in Southern Sudan (1999-2007): a retrospective study of risk factors and trends.
    Gorski S, Collin SM, Ritmeijer K, Keus K, Gatluak F, Mueller M, Davidson RN.
    PLoS Negl Trop Dis; 2010 Jun 08; 4(6):e705. PubMed ID: 20544032
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of liposomal amphotericin B (AmBisome) in the treatment of persistent post-kala-azar dermal leishmaniasis (PKDL).
    Musa AM, Khalil EA, Mahgoub FA, Hamad S, Elkadaru AM, El Hassan AM.
    Ann Trop Med Parasitol; 2005 Sep 08; 99(6):563-9. PubMed ID: 16156969
    [Abstract] [Full Text] [Related]

  • 18. Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.
    Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S.
    Trans R Soc Trop Med Hyg; 2003 Sep 08; 97(3):350-4. PubMed ID: 15228258
    [Abstract] [Full Text] [Related]

  • 19. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection.
    Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN.
    Clin Infect Dis; 2006 Aug 01; 43(3):357-64. PubMed ID: 16804852
    [Abstract] [Full Text] [Related]

  • 20. Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial.
    Hailu A, Musa A, Wasunna M, Balasegaram M, Yifru S, Mengistu G, Hurissa Z, Hailu W, Weldegebreal T, Tesfaye S, Makonnen E, Khalil E, Ahmed O, Fadlalla A, El-Hassan A, Raheem M, Mueller M, Koummuki Y, Rashid J, Mbui J, Mucee G, Njoroge S, Manduku V, Musibi A, Mutuma G, Kirui F, Lodenyo H, Mutea D, Kirigi G, Edwards T, Smith P, Muthami L, Royce C, Ellis S, Alobo M, Omollo R, Kesusu J, Owiti R, Kinuthia J, Leishmaniasis East Africa Platform (LEAP) group.
    PLoS Negl Trop Dis; 2010 Oct 26; 4(10):e709. PubMed ID: 21049059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.